A gorilla-derived adenovirus platform offers a novel edge for cancer therapy due to its naturally embedded therapeutic properties. This vector exhibits low human seroprevalence, reduced liver sequestration, and selective replication in cancer cells, addressing key challenges in current virotherapy. Its substantial cargo capacity also surpasses that of adeno-associated viruses, making it suitable for delivering large transgenes and enabling oncolytic viruses to act as localized delivery systems for complex biologics, thereby enhancing antitumor immune responses.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.





